Month in Review

Fintan Walton hosts the Month in Review in which experts from PharmaVentures discuss some of October’s key deals and what they have meant for the companies involved. The first deal to be covered is the US$1 B development and commercialisation agreement between GlaxoSmithKline and Synta Pharmaceuticals for a first-in-class oxidative stress inducer, STA-4783, indicated for metastatic melanoma. The panel then moves on to talk about Inverness Medical Innovations’ recent acquisitions of Bio-Stat Healthcare and Panbio, how they fit in with the company’s strategy and how they relate to the diagnostics sector in general. The next topic of discussion is Galenica’s all-cash acquisition of Aspreva. Our experts discuss the risk associated with the deal and the success of Aspreva’s business model. Finally, the recently announced licensing agreement between Nycomed and NPS Pharmaceuticals for the gastrointestinal therapy Gattex™ is covered, and the panel offers its views on the impact the deal has had on the two companies.

To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.

• Nycomed and NPS Pharmaceuticals Enter Licensing Agreement for Gattex™
• Inverness Medical Innovations Acquires Bio-Stat Healthcare
• Inverness Medical Innovations Agrees to Acquire Panbio
• GlaxoSmithKline and Synta Pharmaceuticals Enter into Development and Commercialisation Collaboration for STA-4783 in Oncology
• Aspreva to be Acquired by Galenica for US$915 M